Brokerages Anticipate Aptose Biosciences Inc. (NASDAQ:APTO) to Announce -$0.13 Earnings Per Share

Equities research analysts expect that Aptose Biosciences Inc. (NASDAQ:APTO – Get Rating) (TSE:APS) will post earnings of ($0.13) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Aptose Biosciences’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.14). Aptose Biosciences posted earnings of ($0.15) per share during the same quarter last year, which would indicate a positive year over year growth rate of 13.3%. The firm is scheduled to report its next earnings results on Monday, January 1st.

On average, analysts expect that Aptose Biosciences will report full-year earnings of ($0.57) per share for the current fiscal year, with EPS estimates ranging from ($0.64) to ($0.51). For the next year, analysts expect that the company will report earnings of ($0.60) per share, with EPS estimates ranging from ($0.64) to ($0.53). Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Aptose Biosciences.

Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) last issued its earnings results on Monday, May 9th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.03. During the same quarter in the previous year, the firm posted ($0.18) EPS.

Several equities analysts have recently weighed in on APTO shares. StockNews.com raised shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, May 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Aptose Biosciences in a report on Friday, April 1st. Finally, HC Wainwright restated a “buy” rating on shares of Aptose Biosciences in a report on Wednesday, March 23rd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $7.50.

Several institutional investors have recently modified their holdings of APTO. WealthShield Partners LLC grew its stake in Aptose Biosciences by 40.8% in the 4th quarter. WealthShield Partners LLC now owns 104,920 shares of the biotechnology company’s stock valued at $142,000 after acquiring an additional 30,408 shares during the last quarter. Two Sigma Investments LP purchased a new position in Aptose Biosciences in the third quarter valued at approximately $477,000. 683 Capital Management LLC raised its holdings in Aptose Biosciences by 42.1% in the third quarter. 683 Capital Management LLC now owns 3,112,737 shares of the biotechnology company’s stock valued at $6,786,000 after buying an additional 921,530 shares during the period. Goldman Sachs Group Inc. raised its holdings in Aptose Biosciences by 12.5% in the third quarter. Goldman Sachs Group Inc. now owns 751,802 shares of the biotechnology company’s stock valued at $1,639,000 after buying an additional 83,314 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in Aptose Biosciences in the third quarter valued at approximately $1,576,000. Institutional investors and hedge funds own 34.21% of the company’s stock.

Shares of NASDAQ APTO traded down $0.01 during trading on Monday, hitting $1.06. The company had a trading volume of 3,235 shares, compared to its average volume of 421,274. The stock has a fifty day simple moving average of $1.20 and a two-hundred day simple moving average of $1.44. Aptose Biosciences has a fifty-two week low of $0.90 and a fifty-two week high of $5.78. The firm has a market capitalization of $97.76 million, a price-to-earnings ratio of -1.60 and a beta of 1.50.

About Aptose Biosciences (Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Read More